Shanghai Kehua Bio-engineering Co Ltd

Overview

Shanghai Kehua Bio-engineering Co Ltd (KHB) is a medical device company that develops, manufactures and markets in vitro diagnostic devices and related products. The company’s product portfolio includes enzyme immunoassay kits, clinical chemistry reagents, PCR kits, rapid test kits, chemiluminescence reagents; and laboratory instruments such as clinical chemistry analyzers, electrolyte analyzers, microplate readers, nucleic acid extractors, automatic chemiluminescence analyzers, and among others. The company has sales supports facilities in major cities in China and it markets products in China and other countries through distributors. KHB is headquartered in Shanghai, China.
Key Stats
Address
No.1189, Qinzhou North Road, Xuhui District, Xuhui District, SHANGHAI, Shanghai
Headquarters

China

Contact

86 21 64954576

Website
www.skhb.com
No of Employees

1,922

Industry

Medical Equipment

Ticker Symbol & Exchange​

002022 [SZSE]

Revenue (2020)

$602 m

72.2% (2020 vs 2019)
Net Income (2020)

$98 m

234.4% (2020 vs 2019)
Net Profit Margin

16 %

93.7% (2020 vs 2019)
Market Cap *

$1,101 m

EPS *

$0.2

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Shanghai Kehua Bio-engineering Co LtdSiemens Healthineers AGShenzhen Mindray Bio-Medical Electronics Co LtdDaan Gene Co Ltd
Key Information
Headquarters China Germany China China
Headquarter City SHANGHAI ERLANGEN SHENZHEN GUANGZHOU
Headquarter State/Province Shanghai - Guangdong Guangdong
No. of Employees 1,922 65,400 11,833 1,573
Entity Type Public Public Public Public

Products & Services

KHB focuses on the research, development, manufacturing and marketing of diagnostic products and laboratory reagents. The company's major products and brands include the following

Products
  • Diagnostic Kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)
  • Diagnostic Kit for SARS-CoV-2 IgM Antibody (ELISA)
  • Diagnostic Kit for SARS-CoV-2 IgG Antibody (ELISA)
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • KHB
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Acquisitions/Mergers/Takeovers In May, the company’s 18.63% stake to be acquired by Zhuhai Baolian Asset Management Co.,…
2018 Acquisitions/Mergers/Takeovers In June, Shanghai Kehua announced its plans to acquire 26.7% stake in Suzhou Hybiome Biomedical…
2017 Contracts/Agreements In January, the company entered into strategic alliance and distribution agreement with Biokit .
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Technogenetics Srl

Address

Corso Vittorio Emanuele II, Milano
Italy

Telephone

39 0371 1921800

Website

www.technogenetics.it

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
12 May 2021 Shengxiang Biotechnology to Acquire 18.63% Stake in Shanghai Kehua Bio-Engineering for USD303.3 Million Acquisition Shengxiang Biotechnology Co Ltd Shanghai Kehua Bio-engineering Co Ltd
13 May 2020 Zhuhai Baolian Asset Management Plans to Acquire Shanghai Kehua Bio-Engineering Acquisition Zhuhai Baolian Asset Management Co Ltd Shanghai Kehua Bio-engineering Co Ltd
29 Jun 2018 Shanghai Kehua Plans to Acquire 26.6983% Stake in Suzhou Hybiome Biomedical Engineering for USD50.7 Million Acquisition Shanghai Kehua Bio-engineering Co Ltd Suzhou Hybiome Biomedical Engineering Co Ltd
30 Aug 2017 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
04 Nov 2015 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
04 Nov 2015 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

15

Active Jobs

0

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
Conversion/production engineer or technician Shanghai Kehua Bio-engineering Co Ltd China
R&D engineer of medical laboratory reagents (biochemical, immunological and molecular) Shanghai Kehua Bio-engineering Co Ltd China
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar